Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral melatonin as adjunctive therapy for neonatal sepsis
IRCT20260406069025N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in neonatal sepsis comparing Melatonin plus standard treatment with Placebo plus standard treatment (2 arms). Primary endpoint: C-reactive protein level at 72 hours. Started Oct 2026; status: completed.
02
Drugs
melatonin
03
Conditions
neonatal sepsis
Beyond the preview
Go deeper on IRCT20260406069025N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260406069025N1.